Chiromics inks discovery deals with Bristol-Myers, GSK
Chiromics entered research alliances with the two drugmakers, licensing its proprietary compound collection and screening technology. BMS is looking to discover small-molecule therapies with Chiromics' help, and GSK is pursuing undisclosed biological targets, according to the CRO.
The big draw was Chiromics' discovery platform, licensed from the MacMillan Laboratories at Princeton University, which offers a diverse collection of molecules that is more complex than and differentiated from existing small-molecule libraries, the company said. Both deals also include the rights to use Chalis, Chiromics' affinity-selection algorithm, to identify lead molecules.
The two deals demonstrate Chiromics value in the world of drug discovery, founder David MacMillan said in a statement, authenticating "that Chiromics' chemical technology and discovery platform is a unique gateway to a new set of small molecules for drug discovery."